Skip to main content

Table 2 MMRM results for ADAS-cog13 at week 6 (visit 3) and week 12 (visit 5)

From: A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil

Visit

Treatment group

n

LS mean (SE)

80% CI

Difference (SE)

80% CI for difference

Two-sided

P value

Week 6

SAM-760

84

−0.71 (0.50)

−1.36, −0.06

0.74 (0.70)

−0.16, 1.64

0.29

Placebo

93

−1.45 (0.48)

−2.06, −0.83

Week 12

SAM-760

78

0.11 (0.63)

−0.70, 0.92

0.70 (0.87)

−0.42, 1.82

0.43

Placebo

86

−0.58 (0.60)

−1.36, 0.19

  1. ADAS-cog13 Alzheimer’s Disease Assessment Scale-cognitive subscale, CI confidence interval, LS least squares, MMRM mixed model repeated measures, SE standard error